Loading company
enGene Therapeutics Inc.
ENGN · Nasdaq · Healthcare · Biotechnology
$1.95-1.5%Sep 29 close
- 1M
- +6.8%
- 6M
- -68.4%
- 1Y
- -71.4%
ENGN · Nasdaq · Healthcare · Biotechnology
$1.95-1.5%Sep 29 close
The quarter ending July 31, 2026, against the same quarter a year earlier.
| Measure | 3 months toJul 31, 2026 | 3 months toJul 31, 2025 | Change |
|---|---|---|---|
| Profit | -$32.5M | -$29M | -12.11% |
| Profit per share | -$0.47 | -$0.57 | +17.54% |
| Free Cash Flow | -$18.9M | -$26.3M | +28.07% |
These are single quarters, not a trailing year — the figures elsewhere on this site cover twelve months and will be much larger. A seasonal business swings a long way between the two: ServiceNow earns $2.0B of free cash flow in its December quarter and $0.5B in its June one.
Compared against the same quarter a year earlier, not against an analyst forecast. A “beat” or “miss” needs a consensus estimate, which is licensed data we do not carry — and getting it wrong is worse than leaving it out.
enGene Therapeutics Inc. has no earnings call transcript available.
“As we move through the second half of 2026, our focus is on maturing regulatory endpoints data from LEGEND’s pivotal cohort and our planned engagement with the FDA regarding a BLA filing for detalimogene,”
Quoted verbatim from the release, and shown only when the filing attributes it to a named person.
Releases land after the close or before the open, so the move is the session that follows.
Invasive Bladder Cancer (NMIBC) Non-muscle invasive bladder cancer (NMIBC) is a disease that poses a significant burden on both patients and clinics and has a massive economic impact on the healthcare system. NMIBC occurs when cancer cells grow in the tissues that line the interior of the bladder, but the cancer has not yet penetrated the muscle of the bladder wall. NMIBC can present as papillary outgrowths from the bladder wall, which are typically resected, or as carcinoma in situ (CIS), which consists of flat, multifocal lesions that cannot be resected. The two forms can also co-occur. About 75%-80% of new bladder cancer diagnoses are NMIBC. Patients suffering from high-risk NMIBC who are unresponsive to the standard of care, Bacillus Calmette-Guérin (BCG), face high rates of disease recurrence (50%-70%) and are potentially subject to full removal of the bladder (cystectomy) as a curative but life-altering next step.
The company’s own description, as it appears at the foot of the release.
The quote and the company description come from enGene Therapeutics Inc.’s Item 2.02 8-K filed September 8, 2026; the table is built from its quarterly reports. Read the release on EDGAR Share prices are split- and dividend-adjusted.